Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study
Objetives: The incidence of posttransplant diabetes and the elevated cardiovascular (CV) risk among transplant recipients are on the rise. Glucagon-like peptide agonists have the potential to mitigate the effects of immunosuppressive drugs, addressing both hyperglycemia and weight gain. This makes...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Associação Brasileira de Transplante de Órgãos
2024-04-01
|
| Series: | Brazilian Journal of Transplantation |
| Subjects: | |
| Online Access: | https://bjt.emnuvens.com.br/revista/article/view/563 |
| _version_ | 1797211747873980416 |
|---|---|
| author | Joana Freitas José Silvano Catarina Ribeiro Jorge Malheiro Sofia Pedroso Manuela Almeida Isabel Fonseca La Salete Martins |
| author_facet | Joana Freitas José Silvano Catarina Ribeiro Jorge Malheiro Sofia Pedroso Manuela Almeida Isabel Fonseca La Salete Martins |
| author_sort | Joana Freitas |
| collection | DOAJ |
| description |
Objetives: The incidence of posttransplant diabetes and the elevated cardiovascular (CV) risk among transplant recipients are on the rise. Glucagon-like peptide agonists have the potential to mitigate the effects of immunosuppressive drugs, addressing both hyperglycemia and weight gain. This makes them appealing for use in this population, given their CV and renoprotective benefits. Nevertheless, there is insufficient substantial evidence regarding their efficacy in diabetic kidney transplant recipients (KTR). Methods: The objective of this retrospective study was to assess the effectiveness and safety of glucagon-like peptide agonists in KTR. The primary focus was to evaluate their impact on various parameters, such as hemoglobin A1c levels, body mass index (BMI), lipid panel, hemoglobin levels, renal allograft function (estimated glomerular filtration rate [eGFR]), and urinary protein-to-creatinine ratio. Results: During a median observation period of 18 months, this investigation included 64 renal transplant patients. Median eGFR at baseline was 61.9 mL/min/1.73 m2 and remained stable throughout the follow-up. Median HbA1c decreased from 7.5 to 7% (95%CI; p < 0.002). A significant improvement in BMI and lipid panel were also observed. We did not observed significant changes regarding median creatinine and urinary protein:creatinine ratio levels. No side effects justified discontinuation of the drug. Conclusion: This study shows that the use of glucagon-like peptide agonists is feasible and well-tolerated in KTR, with no significant side effects observed. Subsequent studies are needed to explore whether glucagonlike peptide agonists can effectively improve allograft survival in these patients.
|
| first_indexed | 2024-04-24T10:31:25Z |
| format | Article |
| id | doaj.art-8a1bd89554d04454af33627483c91aef |
| institution | Directory Open Access Journal |
| issn | 2764-1589 |
| language | English |
| last_indexed | 2024-04-24T10:31:25Z |
| publishDate | 2024-04-01 |
| publisher | Associação Brasileira de Transplante de Órgãos |
| record_format | Article |
| series | Brazilian Journal of Transplantation |
| spelling | doaj.art-8a1bd89554d04454af33627483c91aef2024-04-12T15:52:05ZengAssociação Brasileira de Transplante de ÓrgãosBrazilian Journal of Transplantation2764-15892024-04-0127Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center StudyJoana Freitas0José Silvano1Catarina Ribeiro2Jorge Malheiro3Sofia Pedroso4Manuela Almeida5Isabel Fonseca6La Salete Martins7Centro Hospitalar Universitário de Santo António – Porto – Portugal.Centro Hospitalar Universitário de Santo António – Porto – Portugal.Centro Hospitalar Universitário de Santo António – Porto – Portugal.Centro Hospitalar Universitário de Santo António – Porto – Portugal.Centro Hospitalar Universitário de Santo António – Porto – Portugal.Centro Hospitalar Universitário de Santo António – Porto – Portugal.Centro Hospitalar Universitário de Santo António – Porto – Portugal.Centro Hospitalar Universitário de Santo António – Porto – Portugal. Objetives: The incidence of posttransplant diabetes and the elevated cardiovascular (CV) risk among transplant recipients are on the rise. Glucagon-like peptide agonists have the potential to mitigate the effects of immunosuppressive drugs, addressing both hyperglycemia and weight gain. This makes them appealing for use in this population, given their CV and renoprotective benefits. Nevertheless, there is insufficient substantial evidence regarding their efficacy in diabetic kidney transplant recipients (KTR). Methods: The objective of this retrospective study was to assess the effectiveness and safety of glucagon-like peptide agonists in KTR. The primary focus was to evaluate their impact on various parameters, such as hemoglobin A1c levels, body mass index (BMI), lipid panel, hemoglobin levels, renal allograft function (estimated glomerular filtration rate [eGFR]), and urinary protein-to-creatinine ratio. Results: During a median observation period of 18 months, this investigation included 64 renal transplant patients. Median eGFR at baseline was 61.9 mL/min/1.73 m2 and remained stable throughout the follow-up. Median HbA1c decreased from 7.5 to 7% (95%CI; p < 0.002). A significant improvement in BMI and lipid panel were also observed. We did not observed significant changes regarding median creatinine and urinary protein:creatinine ratio levels. No side effects justified discontinuation of the drug. Conclusion: This study shows that the use of glucagon-like peptide agonists is feasible and well-tolerated in KTR, with no significant side effects observed. Subsequent studies are needed to explore whether glucagonlike peptide agonists can effectively improve allograft survival in these patients. https://bjt.emnuvens.com.br/revista/article/view/563Glucagon-like Peptide-1 Receptor AgonistsKidney TransplantDiabetes Mellitus |
| spellingShingle | Joana Freitas José Silvano Catarina Ribeiro Jorge Malheiro Sofia Pedroso Manuela Almeida Isabel Fonseca La Salete Martins Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study Brazilian Journal of Transplantation Glucagon-like Peptide-1 Receptor Agonists Kidney Transplant Diabetes Mellitus |
| title | Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study |
| title_full | Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study |
| title_fullStr | Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study |
| title_full_unstemmed | Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study |
| title_short | Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study |
| title_sort | glucagon like peptide 1 receptor agonists in kidney transplant recipients a retrospective single center study |
| topic | Glucagon-like Peptide-1 Receptor Agonists Kidney Transplant Diabetes Mellitus |
| url | https://bjt.emnuvens.com.br/revista/article/view/563 |
| work_keys_str_mv | AT joanafreitas glucagonlikepeptide1receptoragonistsinkidneytransplantrecipientsaretrospectivesinglecenterstudy AT josesilvano glucagonlikepeptide1receptoragonistsinkidneytransplantrecipientsaretrospectivesinglecenterstudy AT catarinaribeiro glucagonlikepeptide1receptoragonistsinkidneytransplantrecipientsaretrospectivesinglecenterstudy AT jorgemalheiro glucagonlikepeptide1receptoragonistsinkidneytransplantrecipientsaretrospectivesinglecenterstudy AT sofiapedroso glucagonlikepeptide1receptoragonistsinkidneytransplantrecipientsaretrospectivesinglecenterstudy AT manuelaalmeida glucagonlikepeptide1receptoragonistsinkidneytransplantrecipientsaretrospectivesinglecenterstudy AT isabelfonseca glucagonlikepeptide1receptoragonistsinkidneytransplantrecipientsaretrospectivesinglecenterstudy AT lasaletemartins glucagonlikepeptide1receptoragonistsinkidneytransplantrecipientsaretrospectivesinglecenterstudy |